Eritoran, a TLR4 antagonist, and sunitinib, a tyrosine kinase inhibitor that regulates the expression of MKI67, both showed high positive correlations with hub genes and may be considered potential targeted treatments for ROP (Figure 9). This evidence concerns the gene TLR4 and retinopathy of prematurity.